Table 1 Baseline patient demographics
From: Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
Esaxerenone | ||
|---|---|---|
Monotherapy (n = 33) | Add-on therapy (n = 58) | |
Male, n (%) | 24 (72.7) | 45 (77.6) |
Age, years | 63.9 ± 7.9 | 68.0 ± 7.7 |
≥65 years, n (%) | 17 (51.5) | 41 (70.7) |
Body mass index, kg/m2 | 25.7 ± 3.1 | 25.2 ± 3.9 |
≥25 kg/m2, n (%) | 16 (48.5) | 29 (50.0) |
Systolic BP, mmHg | 153.6 ± 7.3 | 159.4 ± 10.9 |
≥160 mmHg, n (%) | 7 (21.2) | 30 (51.7) |
Diastolic BP, mmHg | 93.4 ± 6.7 | 91.8 ± 7.3 |
≥100 mmHg, n (%) | 6 (18.2) | 8 (13.8) |
eGFR, mL/min/1.73 m2 | 51.9 ± 7.2 | 50.9 ± 6.5 |
<45 mL/min/1.73 m2, n (%) | 7 (21.2) | 12 (20.7) |
Serum K+, mEq/L | 4.2 ± 0.3 | 4.3 ± 0.3 |
≥4.5 mEq/L, n (%) | 5 (15.2) | 17 (29.3) |
Hypertension duration, years | 11.4 ± 10.7 | 11.0 ± 6.6 |
Pretreatment with antihypertensive agents, n (%) | 24 (72.7) | 51 (87.9) |
ARB | – | 56 (96.6) |
ACEi | – | 2 (3.4) |
Diabetes, n (%) | 13 (39.4) | 13 (22.4) |
HbA1c, % | 6.1 ± 0.8 | 5.8 ± 0.5 |
≥6.9%, n (%) | 7 (21.2) | 2 (3.4) |
Blood glucose, mg/dL | 115.6 ± 20.5 | 104.2 ± 17.7 |
UACR, mg/g•Cr | 16.7 ± 33.5 | 49.5 ± 112.1a |
≥30 mg/g•Cr, n (%) | 3 (9.1) | 13 (22.4)a |
Plasma aldosterone concentration, pg/mL | 108.1 ± 45.0 | 93.9 ± 34.7 |
Plasma renin activity, ng/mL/h | 0.8 ± 0.7 | 1.6 ± 1.6b |
